Last updated: 2026-09-06 04:12:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Achieve Life Sciences, Inc. (ACHV) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $8.49, with a market capitalisation of $872.61M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.62 to $8.64. This page covers its latest market performance, valuation, price trends and company information.
$872.61M | |
$8.20 | |
$970.00 | |
$1.84 | |
$8.31 | |
795.11K | |
-- | |
-- | |
$8.64 | |
$2.62 | |
-- | |
-- |
Achieve Life Sciences, Inc. (ACHV) last closed at $8.31 as of 2026-09-04 23:56:00, unchanged from the previous close of $8.31.
During the latest regular trading session, ACHV traded between $1.84 and $970.00, with a volume of 795.11K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Achieve Life Sciences, Inc. (ACHV) moved from $8.07 to $8.49, representing a gain of 5.25% ($0.42).
The stock traded between $8.20 and $8.54 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.16 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 97.6%
ACHV is currently trading at $8.49, placing it 97.6% of the way from its 52-week low of $2.62 to its 52-week high of $8.64. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Achieve Life Sciences, Inc. (ACHV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.